Myotubular Myopathy Event Study (MTMES)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01840657|
Recruitment Status : Completed
First Posted : April 26, 2013
Last Update Posted : March 7, 2018
X-Linked myotubular myopathy (XLMTM), a form of centronuclear myopathy (CNM) is the result of a mutation in the MTM1 (myotubularin) gene which leads to altered myotubularin. Myotubularin is essential for optimum muscle function. To date, over 100 mutations have been described resulting in a range of disease onset and symptom severity. The early onset form presents with neonatal hypotonia, muscle weakness, respiratory distress and an ongoing requirement for continuous ventilatory support with the inability to maintain a sitting position once placed. Males with both later onset and milder symptoms usually do not require ongoing ventilatory support, achieve a higher maximal motor function with ability to sit when placed and even walk, and have improved survival rates. Males with XLMTM may experience complications (events) at birth and throughout their lifetime. The goal of the study is to identify the number of events over twelve months in males with genetically confirmed XLMTM. Parents or affected individuals over the age of 18 years who are able to access telephone will provide answers to an established event survey to evaluate the frequency and types of events. Emergency department, hospital admissions and mortality will be confirmed by obtaining medical reports.
The investigators hypothesize that there will be no association between the frequency of events and markers of clinical severity including the need for ventilatory support at birth, current level of ventilatory support (no support, support less than 12 hours, support more than 12 hours) and current motor function (walking, sitting without support, inability to sit without support).
|Condition or disease|
|X-linked Myotubular Myopathy|
|Study Type :||Observational|
|Actual Enrollment :||33 participants|
|Official Title:||Prospective Study of Adverse Event Rates in Males With X-Linked Myotubular Myopathy|
|Actual Study Start Date :||April 2013|
|Actual Primary Completion Date :||October 2015|
|Actual Study Completion Date :||October 2015|
- Survey of a defined set of events [ Time Frame: 12 months ]Changes in care needed, breathing support, motor ability, medications and medical care, nutrition/weight management, communication/vision/learning/behavior, and frequency of outpatient/hospital/ER visits are recorded by a monthly telephone survey.
- Frequency of a predefined set of events related to ventilatory status [ Time Frame: 12 months ]To analyze the strength of the association between the frequency of events surveyed and 1) duration of ventilatory support directly after birth and 2) current need for ventilatory support.
- Frequency of a predefined set of events related to current motor function [ Time Frame: 12 months ]To analyze the strength of the association between the frequency of events surveyed and current motor function
- Association between event frequency and genotype [ Time Frame: 12 months ]To determine the strength of the association between the frequency of the events surveyed and the affected individual's genotype.
- Association between event rate and season [ Time Frame: 12 months ]To analyze event rates with respect to two seasonal clusters, October through March and April through September.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01840657
|United States, California|
|Torrance, California, United States, 90502|
|Principal Investigator:||Joseph Hornyak, MD, PhD||University of Michigan|
|Principal Investigator:||Anne Rutkowski, MD||Cure CMD|
|Principal Investigator:||James Dowling, MD, PhD||University of Michigan|